INKT (MiNK Therapeutics Inc.) stock: $9.07, $46.5M market cap, $7.5M cash, $39.0M EV, $56.7M fully diluted market cap. Next expected readout: Jun-27. Lead program: agenT-797 (Pneumonia), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our approach includes advancing both native and engineered iNKT cell therapies, leveraging a pipeline composed of wholly owned or exclusively licensed assets. Additionally, we have developed a proprietary personalized neoantigen library to facilitate personalized T Cell Receptor ("TCR") development.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Agenus (iNKT platform patent rights and know-how assigned; field-limited license back); Memorial Sloan Kettering Cancer Center (Phase 2 investigator-sponsored trial, NCT06251973); First Lviv Territorial Medical Union / UNBROKEN Ukraine (Phase 2 pulmonary trial); University of Wisconsin-Madison (Phase 1 investigator-sponsored GvHD prevention trial); NIH/NIAID (STTR grant supporting preclinical and clinical development); Mary Gooze Clinical Trial Award (funds GvHD trial enrollment and operations)
Indications
critical pulmonary immune failure (severe pneumonia with moderate-to-severe hypoxemic acute respiratory failure)(Stage not disclosed)
refractory solid tumor cancers (monotherapy and in combination with anti-PD-1 agents)(Stage not disclosed)
advanced esophageal, gastric, and gastroesophageal junction adenocarcinoma (Phase 2 investigator-sponsored combination with botensilimab and balstilimab)(Stage not disclosed)
graft-versus-host disease prevention in allogeneic HSCT recipients (Phase 1 investigator-sponsored)(Stage not disclosed)
interstitial lung disease and idiopathic pulmonary fibrosis (potential expansion)(Stage not disclosed)
Catalysts
— None
— None
Status note Most advanced product candidate; nearly 100 patients treated across oncology and critical pulmonary immune failure. No lymphodepletion required; activity independent of HLA matching.
MiNK-215
Discovery · ActiveModality: CAR-iNKT cell therapy
Target FAP (fibroblast activation protein)
Indications
cancer (not specified)(Stage not disclosed)
Status note Engineered FAP-targeted CAR-iNKT candidate in discovery; part of engineered iNKT pipeline.
MiNK-413
Discovery · ActiveModality: CAR-iNKT cell therapy
Target BCMA (B-cell maturation antigen)
Indications
cancer (not specified)(Stage not disclosed)
Status note Engineered BCMA-targeted CAR-iNKT candidate in discovery; part of engineered iNKT pipeline.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.